Krystal Biotech (KRYS) Total Non-Current Liabilities (2018 - 2026)

Krystal Biotech has disclosed Total Non-Current Liabilities across 5 years of filings, most recently posting $115.1 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $115.1 million, up 31.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.1 million (up 31.13% YoY), and the FY2025 annual result was $110.5 million, up 2.31% from the prior year.
• Total Non-Current Liabilities came in at $115.1 million for Q1 2026 at Krystal Biotech, up from $110.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $115.1 million in Q1 2026 to a low of $39.7 million in Q4 2023.
• The 4-year median for Total Non-Current Liabilities is $95.7 million (2024), against an average of $92.1 million.
• Across the five-year window, Total Non-Current Liabilities jumped 172.04% in 2024 and gained 2.31% in 2025, its largest moves.
• Krystal Biotech's Total Non-Current Liabilities stood at $39.7 million in 2023, then surged by 172.04% to $108.0 million in 2024, then climbed by 2.31% to $110.5 million in 2025, then advanced by 4.14% to $115.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $115.1 million (Q1 2026), $110.5 million (Q4 2025), and $99.1 million (Q3 2025), per Business Quant data.